PAPER Schneider C, Prokopiou PC, Papp KV, Engels-Domínguez N, Hsieh S, Juneau TA, Schultz AP, Rentz DM, Sperling RA, Johnson KA, Jacobs HI
SEARCH RESULTS
1348 RESULTS
PAPER Kharaghani A, Tio ES, Milic M, Bennett DA, De Jager PL, Schneider JA, Sun L, Felsky D
Association of whole-person eigen-polygenic risk scores with Alzheimer's disease.
Hum Mol Genet. 2024 Apr 27; PubMed: 38679805PAPER Sun C, Dong S, Chen W, Li J, Luo E, Ji J
Berberine alleviates Alzheimer's disease by regulating the gut microenvironment, restoring the gut barrier and brain-gut axis balance.
Phytomedicine. 2024 Apr 21;129:155624. PubMed: 38678955PAPER Bianco MG, Cristiani CM, Scaramuzzino L, Sarica A, Augimeri A, Chimento I, Buonocore J, Parrotta EI, Quattrone A, Cuda G, Quattrone A
Combined blood Neurofilament light chain and third ventricle width to differentiate Progressive Supranuclear Palsy from Parkinson's Disease: A machine learning study.
Parkinsonism Relat Disord. 2024 Apr 24;123:106978. PubMed: 38678852PAPER Mayo P, Pascual J, Crisman E, Domínguez C, López MG, León R
Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment.
Med Res Rev. 2024 Apr 28; PubMed: 38678582PAPER Oosthoek M, Vermunt L, de Wilde A, Bongers B, Antwi-Berko D, Scheltens P, van Bokhoven P, Vijverberg EG, Teunissen CE
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review.
Alzheimers Res Ther. 2024 Apr 27;16(1):93. PubMed: 38678292PAPER Ko VI, Ong K, Cleveland DW, Yu H, Ravits JM
CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation.
Neurobiol Dis. 2024 Apr 25;196:106516. PubMed: 38677657PAPER Hölscher C
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Neuropharmacology. 2024 Apr 25;253:109952. PubMed: 38677445PAPER Couto B, Di Luca DG, Antwi J, Bhakta P, Fox S, Tartaglia MC, Kovacs GG, Lang AE
Ethnic background and distribution of clinical phenotypes in patients with probable progressive supranuclear palsy.
Parkinsonism Relat Disord. 2024 Apr 15;123:106955. PubMed: 38677215PAPER Nikitina MA, Koroleva ES, Brazovskaya NG, Boyko AS, Levchuk LA, Ivanova SA, Alifirova VM
[Associations of serum neuromarkers with clinical features of Parkinson's disease].
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):145-152. PubMed: 38676689PAPER Berezutsky MA, Durnova NA, Andronova TA
[Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer's disease].
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):22-27. PubMed: 38676673PAPER Kashchenko SA, Eranova AA, Chuguy EV
[Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer's disease].
Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):7-12. PubMed: 38676671PAPER Dash BP, Freischmidt A, Weishaupt JH, Hermann A
An integrative miRNA-mRNA expression analysis identifies miRNA signatures associated with SOD1 and TARDBP patient-derived motor neurons.
Hum Mol Genet. 2024 Apr 27; PubMed: 38676626PAPER Li H, Hua Q, Cheng S, Liu X, Cai Q, Zhang J, Peng T, Li J, Wang C, Liang C, Shi Y, Wang X, Tan Y
The NeuroProtect Formula: A Preventive Approach to AD Targeting the HIF-1/PI3K-AKT Signaling Pathway Evaluated through In Vivo, In Vitro, and Network Pharmacology Approaches.
Comb Chem High Throughput Screen. 2024 Apr 26; PubMed: 38676511PAPER Vishwas S, Bashir B, Birla D, Khandale N, Chaitanya MV, Chellappan DK, Gupta G, Negi P, Dua K, Singh SK